LONG TERM EFFICACY AND SURVIVAL IN PATIENTS TREATED WITH THE GUT-SELECTIVE ANTIBIOTIC RIFAXIMIN (550 MG BID) FOR THE MAINTENANCE OF REMISSION FROM OVERT HEPATIC ENCEPHALOPATHY

被引：3
|
作者：
Mullen, K. D. [1 ]
Poordad, F. [2 ]
Rossaro, L. [3 ]
Jamal, M. [4 ]
Talwalkar, J. [5 ]
Huang, S. [6 ]
Merchant, K. [6 ]
Bortey, E. [6 ]
Forbes, W. P. [6 ]
机构：
[1] Case Western Reserve Univ, Metrohlth Med Ctr, Cleveland, OH USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[3] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA
[4] Long Beach VA Med Ctr, Long Beach, CA USA
[5] Mayo Rochester, Rochester, MN USA
[6] Salix Pharmaceut Inc, Morrisville, NC USA
来源：
JOURNAL OF HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
10.1016/S0168-8278(11)60111-6
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
109
引用
收藏
页码：S49 / S49
页数：1
相关论文
共 9 条
  • [1] The Long Term Efficacy and Safety of Rifaximin in the Maintenance of Remission From Overt Hepatic Encephalopathy in Cirrhotic Patients
    Mullen, Kevin D.
    Sanyal, Arun J.
    Bass, Nathan M.
    Poordad, Fred
    Huang, Shirley
    Merchant, Kunal
    Bortey, Enoch
    Forbes, William P.
    GASTROENTEROLOGY, 2012, 142 (05) : S41 - S42
  • [2] Rifaximin Is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt Hepatic Encephalopathy
    Mullen, Kevin D.
    Sanyal, Arun J.
    Bass, Nathan M.
    Poordad, Fred F.
    Sheikh, Muhammad Y.
    Frederick, R. Todd
    Bortey, Enoch
    Forbes, William P.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (08) : 1390 - +
  • [3] Rifaximin has a Favorable Long-Term Safety Profile for Maintenance of Remission from Overt Hepatic Encephalopathy
    Sheikh, Muhammad
    Bass, Nathan
    Sanyal, Arun
    Poordad, Fred
    Mullen, Kevin
    Sigal, Samuel
    Frederick, Todd
    Bhandari, Bal Raj
    Vemuru, Ravikumar
    Huang, Shirley
    Merchant, Kunal
    Shaw, Audrey
    Bortey, Enoch
    Forbes, William
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S136 - S136
  • [4] LONG TERM CARE SERVICES USE AMONG MEDICARE PATIENTS TREATED WITH RIFAXIMIN FOR OVERT HEPATIC ENCEPHALOPATHY
    Gagnon-Sanschagrin, Patrick
    Heimanson, Zeev
    Allen, Christopher
    Maitland, Jessica
    Davidson, Mikhail
    Zhang, Adina
    Chen, Jingyi
    Guerin, Annie
    Dashputre, Ankur A.
    Bumpass, Brock
    Olujohungbe, Olamide
    Borroto, Danellys
    Joseph, George
    GASTROENTEROLOGY, 2023, 164 (06) : S1400 - S1400
  • [5] A RESEARCH STUDY TO REGULATE THE EFFICACY OF RIFAXIMIN IN HEPATIC ENCEPHALOPATHY PATIENTS SUFFERING FROM LONG-TERM LIVER DISEASE
    Rehman, Inam Ur
    Amin, Nuzhat
    Batool, Warda Laraib
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 6 (05): : 9947 - 9950
  • [6] Efficacy of tofacitinib dose escalation to 10 mg BID in patients with UC after completing maintenance therapy in remission and losing response: Data from OCTAVE open-label, long-term extension study
    Rubin, D. T.
    Dubinsky, M. C.
    Panes, J.
    Wu, D. C.
    Lawendy, N.
    Guo, X.
    Lai, C.
    Kwok, K.
    Su, C.
    Salese, L.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S112 - S113
  • [7] Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study
    Sands, B. E.
    Moss, A. C.
    Armuzzi, A.
    Marshall, J. K.
    Lindsay, J. O.
    Sandborn, W. J.
    Danese, S.
    Zeroncio, M.
    Modesto, I.
    Salese, L.
    Lawendy, N.
    Zhang, H.
    Su, C.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S110 - S111
  • [8] EFFICACY AND SAFETY OF ESCALATION TO TOFACITINIB 10 MG BID FOR PATIENTS WITH UC FOLLOWING LOSS OF RESPONSE ON 5 MG BID MAINTENANCE THERAPY: RESULTS FROM OCTAVE OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Sands, Bruce E.
    Moss, Alan
    Armuzzi, Alessandro
    Marshall, John K.
    Lindsay, James
    Sandborn, William J.
    Danese, Silvio
    Zeroncio, Marco
    Modesto, Irene
    Salese, Leonardo
    Lawendy, Nervin
    Zhang, Haiying
    Su, Chinyu
    GASTROENTEROLOGY, 2020, 158 (06) : S1189 - S1190
  • [9] EFFICACY OF TOFACITINIB DOSE ESCALATION TO 10 MG BID IN PATIENTS WITH ULCERATIVE COLITIS AFTER COMPLETING MAINTENANCE THERAPY IN REMISSION AND LOSING RESPONSE: DATA FROM OCTAVE OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Rubin, David T.
    Dubinsky, Marla C.
    Panes, Julian
    Wu, Deng-Chyang
    Lawendy, Nervin
    Guo, Xiang
    Lai, Chacun
    Kwok, Kenneth
    Su, Chinyu
    Salese, Leonardo
    GASTROENTEROLOGY, 2020, 158 (06) : S1195 - S1195
1